Omeros (OMER) Return on Invested Capital (2026)

Omeros (OMER) reported Return on Invested Capital of 0.07% for Q1 2026.

Omeros (OMER) Return on Invested Capital (2026) Analysis & Trends

Omeros (OMER) has 1 years of Return on Invested Capital data on file, last reported at 0.07% in Q1 2026.

For the quarter ending Q1 2026, Return on Invested Capital changed N/A year-over-year to 0.07%; the trailing twelve-month figure through Mar 2026 stood at 0.07% (changed N/A YoY), and the FY2025 full-year result was 1.32%, down 28.0% from the prior year.
Return on Invested Capital held at 0.07% in Q1 2026.
In the past five years, Return on Invested Capital ranged from a high of 0.07% in Q1 2026 to a low of 0.07% in Q1 2026.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROIC (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.00%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.04%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Omeros	739.31 Mn	739.31 Mn	9.31 Mn	-0.07%

Historic Data

Download Data

Date	Value
Mar 31, 2026	-0.07%